Statement of Policy Intent: Early Access to Innovative Medical Devices

AI Summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) is advancing its strategy to streamline patient access to innovative medical technologies. This initiative aligns with the UK Government's 10-year Health Plan and the Life Sciences Sector Plan, positioning the UK as a global leader in medical innovation. The core development involves transforming the Unmet Clinical Need Authorisation (UCNA) tool, which was previously part of the Innovative Devices Access Pathway (IDAP) pilot, into a permanent, routine Early Access service. This service is designed to support innovators operating outside structured pathways like IDAP, specifically targeting medical technologies that address significant unmet clinical needs. Under this regulatory framework, the MHRA aims to employ risk-proportionate regulation while providing continuous support to developers. The primary objective is to accelerate the delivery of safe, cutting-edge devices to patients who currently lack effective treatment options. By institutionalizing the UCNA tool, the MHRA seeks to provide a predictable and efficient route for innovative products to enter the UK market, fostering a dynamic environment for clinical advancement.